Table 1 Details of the included studies
Data sets | Articles | Conditions | Active interventions | Patients | Work-related outcomes | Study duration (in weeks) | OQS score |
|---|---|---|---|---|---|---|---|
1 | Albert et al. 2013 [10] | Chr. back pain | Amoxicillin–Clavulanate | 162 | Time lost from work | 52 | 5 |
2 | Baron et al. 2010 [14] | Chr. back pain | Pregabalin | 217 | WPAI | 5 | 4 |
3 | Carlsson & Sjölund 2001 [19] | Chr. back pain | Acupuncture, electroacupuncture | 51 | Employment status | 32 | 5 |
4 | Jarzem et al. 2005 [25] | Chr. back pain | TENS | 350 | McGill Work Scale | 12 | 5 |
5 | Lehmann et al. 1986 [29] | Chr. back pain | TENS, electroacupuncture | 54 | Employment status | 3 | 4 |
6 | Licciardone et al. 2003 [30] | Chr. back pain | Osteopathic manipulative treatment | 91 | Time lost from work | 20 | 3 |
7 | Skljarevski et al. 2009 [34] | Chr. back pain | Duloxetine | 404 | BPI-I | 13 | 5 |
8 | Skljarevski et al. 2010a [35] | Chr. back pain | Duloxetine | 236 | BPI-I, WPAI | 13 | 4 |
9 | Skljarevski et al. 2010b [36] | Chr. back pain | Duloxetine | 401 | BPI-I, WPAI | 12 | 3 |
10 | He et al. 2005 [24] | Chr. neck pain | Body acupuncture + body electrostimulation + ear acupressure | 24 | Activity impairment at work | 4 | 2 |
11 | Manchikanti et al. 2010 [31] | Chr. neck pain | Bupivacaine and steroid injection | 120 | Employability, employment status | 96 | 5 |
12 | Fibromyalgia | Tramadol-Acetaminophen | 315 | FIQ, time lost from work, SF-36 | 8 | 3 | |
13 | Bradley et al. 2010 [18] + Arnold et al. 2009 [12] (Arnold et al. 2005 [11] + Chappell et al. 2008 [20]) | Fibromyalgia | Duloxetine | 1332 | Bradley 2010 [18]: FIQ, Arnold 2009 [12]: SDS (Arnold 2005 [11]: BPI, Chappell 2008 [20]: SDS) | 12-28 | Review (Arnold et al. 2005 [11]: 5, Chappell et al. 2008 [20]: 3) |
14 | Straube et al. 2011 [4] | Fibromyalgia | Pregabalin | 2757 | FIQ, time lost from work, SF-36, SDS, MAF | 8-14 | Review |
15 | Chappell et al. 2009 [21] | Osteoarthritis (knee) | Duloxetine | 231 | BPI-I | 13 | 5 |
16 | Chappell et al. 2011 [22] | Osteoarthritis (knee) | Duloxetine | 256 | BPI-I | 13 | 5 |
17 | Markenson et al. 2005 [32] | Osteoarthritis | Oxycodone | 109 | BPI-I | 12 | 4 |
18 | Kavanaugh et al. 2006 [26] | Psoriatic arthritis | Infliximab | 200 | SF-36, employment status, employability, impact on productivity at work (VAS), time lost from work | 22 | 3 |
19 | Kavanaugh et al. 2013 [28] | Psoriatic arthritis | Golimumab | 405 | Impact on productivity at work (VAS) | 24 | 4 |
20 | Egsmose et al. 1997 [23] | Reactive arthritis | Sulphasalazine | 83 | Time lost from work | 24 | 3 |
21 | Bejarano et al. 2008 [15] | Rheumatoid arthritis | Adalimumab + MTX | 148 | Employment status, WIS, Time lost from work | 56 | 5 |
22 | Kavanaugh et al. 2009 [27] | Rheumatoid arthritis | Certolizumab pegol + MTX | 1601 | WPS, time lost from work | 24 + 52 | 3 |
23 | Meireles et al. 2010 [33] | Rheumatoid arthritis | Low-level laser therapy | 82 | DASH | 8 | 5 |
24 | Smolen et al. 2006 [37] | Rheumatoid arthritis | Infliximab + MTX | 1004 | Employability, time lost from work | 54 | 5 |
25 | Strand et al. 1999 [38] | Rheumatoid arthritis | Leflunomide, MTX | 482 | Productivity at work | 48 | 4 |
26 | Barkham et al. 2010 [13] | Ankylosing spondylitis | Entanercept | 40 | WIS, time lost from work | 12 | 3 |
27 | van der Heijde et al. 2006 [39] | Ankylosing spondylitis | Infliximab | 279 | SF-36, impact on productivity at work (VAS), time lost from work | 24 | 4 |